Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

  • Rockett, Rebecca Ph.D.
  • Basile, Kerri M.D.
  • Maddocks, Susan M.D., Ph.D.
  • Fong, Winkie Ph.D.
  • Agius, Jessica E. Ph.D.
  • Johnson-Mackinnon, Jessica Ph.D.
  • Arnott, Alicia Ph.D.
  • Chandra, Shona Ph.D.
  • Gall, Mailie Ph.D.
  • Draper, Jenny Ph.D.
  • Martinez, Elena Ph.D.
  • Sim, Eby M. Ph.D.
  • Lee, Clement B.S.
  • Ngo, Christine B.S.
  • Ramsperger, Marc Ph.D.
  • Ginn, Andrew N. Ph.D.
  • Wang, Qinning Ph.D.
  • Fennell, Michael M.S.
  • Ko, Danny B.S.
  • Lim, Ling H. M.D.
  • Gilroy, Nicky M.D.
  • O’Sullivan, Matthew V.N. M.D., Ph.D.
  • Chen, Sharon C.-A. M.D., Ph.D.
  • Kok, Jen M.D., Ph.D.
  • Dwyer, Dominic E. M.D.
  • Sintchenko, Vitali M.D., Ph.D.

  • 1University of Sydney, Sydney, NSW, Australia [email protected]

    2NSW Health Pathology, Sydney, NSW, Australia

    3Western Sydney Local Health District, Westmead, NSW, Australia

    4University of Sydney, Sydney, NSW, Australia

    5University of Sydney, Sydney, NSW, Australia [email protected]

This letter was published on March 9, 2022, at NEJM.org.

Supported by the Prevention Research Support Program, which is funded by the New South Wales (NSW) Ministry of Health; NSW Health Covid-19 priority funding; a grant (APPRISE 1116530) from the National Health and Medical Research Council, Australia; and a Jerry Koutts Ph.D. Scholarship (to Dr. Basile) from the Institute of Clinical Pathology and Medical Research.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

New England Journal of Medicine 386(15):p 1477-1479, April 14, 2022. | DOI: 10.1056/NEJMc2120219

Resistance Mutations after Sotrovimab Use

Among the first 100 patients who received sotrovimab, a monoclonal antibody directed against SARS-CoV-2, at a center in Australia, 8 had persistently positive SARS-CoV-2 polymerase-chain-reaction tests. Isolates obtained from 4 patients showed a mutation associated with resistance to sotrovimab in the receptor-binding domain, and cultures were positive at 2 to 3 weeks after treatment.

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

  • Takashita, Emi Ph.D.
  • Kinoshita, Noriko M.D.
  • Yamayoshi, Seiya D.V.M., Ph.D.
  • Sakai-Tagawa, Yuko Ph.D.
  • Fujisaki, Seiichiro Ph.D.
  • Ito, Mutsumi D.V.M.
  • Iwatsuki-Horimoto, Kiyoko D.V.M., Ph.D.
  • Halfmann, Peter Ph.D.
  • Watanabe, Shinji D.V.M., Ph.D.
  • Maeda, Kenji M.D., Ph.D.
  • Imai, Masaki D.V.M., Ph.D.
  • Mitsuya, Hiroaki M.D., Ph.D.
  • Ohmagari, Norio M.D., Ph.D.
  • Takeda, Makoto M.D., Ph.D.
  • Hasegawa, Hideki M.D., Ph.D.
  • Kawaoka, Yoshihiro D.V.M., Ph.D.
New England Journal of Medicine 386(15):p 1475-1477, April 14, 2022. | DOI: 10.1056/NEJMc2201933
Copyright © 2022 Massachusetts Medical Society. All rights reserved.
View full text|Download PDF